PharmaPendium® Adds New Module to Aid Decision Making on Drug Candidates
AMSTERDAM, May 6, 2013 /PRNewswire/ --
PharmaPendium Metabolizing Enzymes and Transporters Module delivers comprehensive visibility of Drug-Drug-Interactions
Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announces that PharmaPendium, the leading source of preclinical, clinical and post-market data, has added a new module to its content base, the Metabolizing Enzymes and Transporters Module.
The addition of the Metabolizing Enzymes and Transporters Module to PharmaPendium's existing content gives researchers a greater understanding and visibility of Drug-Drug Interactions (DDI) and their potential adverse reactions during critical stages of drug discovery and development.
The new module will benefit researchers including toxicologists, pharmacokinetics researchers and departments, safety pharmacologists and clinical pharmacologists, who demand the highest quality data on preclinical and clinical metabolizing enzymes and transporters. These researchers often struggle to find comparative data to understand how changes in the activity of metabolizing enzymes and transporters affect the safety and efficacy of drugs. Currently, available information on DDIs is hard to collate and analyze and is not always normalized for comparison, making data analysis not only labour and cost intensive, but also open to critical error.
PharmaPendium's Metabolizing Enzymes and Transporters Module allows for rapid, full text-search of literature from sources including approval documents from the Food and Drug Administration (FDA) and European Medicines Agency (EMA). It extracts both in vivo and in vitro human and animal experimental data on metabolizing enzymes and transporters contained in preclinical and clinical studies, and applies it to the context of researchers' experiments, facilitating efficient and diligent drug development.
"Identifying potential interactions that impact the efficacy and safety of a drug is a significant challenge," said Philip MacLaughlin, Director of Product Development at Elsevier. "The new module supports early detection of viable drug candidates by providing the highest quality data and enabling comparative assessments of metabolizing enzyme and transporter activities, reducing chances of unpredictable adverse reactions and even late stage clinical failures."
PharmaPendium is part of Elsevier's Life Science Solutions, a suite of interoperable, domain-specific, decision support tools which span the discovery and development workflow, including Reaxys, Reaxys Medicinal Chemistry, ScienceDirect, Scopus, TargetInsights, Pathway Studio and Embase.
PharmaPendium Metabolizing Enzymes and Transporters Module is available now; for more information go to: http://www.elsevier.com/pharmapendium
PharmaPendium decision support tool allows safety assessment teams, toxicologists, pharmacokineticists and project leaders to extract relevant comparative pharmacological and pharmacokinetic information from the entire history of drug development by locating published regulatory and commercial precedents sharing similarities with the class, the target or the structural chemistry of candidate drugs. This allows R&D organizations to make faster, more reliable decisions about which candidate compounds to take forward to pre-clinical phases. http://www.elsevier.com/pharmapendium
PharmaPendium® and the PharmaPendium® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby's Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.
More by this Source
Elsevier and Russia's Ural Federal University Sign License Agreement for Pure
Apr 22, 2014, 08:57 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.